Exosens (EXENS) AI Stock Analysis

• Market Cap: €2.22B
• Dividend Yield: 0.23%
• Average Volume (3M): 138.21K
• Price to Earnings (P/E): 39.2
• Beta (1Y): 0.65
• Revenue Growth: 22.05%
• EPS Growth: 2658.04%
• Country: FR
• Employees: 1,214
• Sector: General
• Sector Strength: N/A
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 0.55
• Shares Outstanding: 50,782,550
• 10 Day Avg. Volume: 251,547
• 30 Day Avg. Volume: 138,212
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €41.00
• Price Target Upside: -6.07% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 70 Outperform
• Price Target: €45.00 ▲(3.09% Upside)

Exosens' overall stock score is driven by strong financial performance, with significant improvements in revenue, profitability, and cash flow. However, the technical analysis presents mixed signals, and the high P/E ratio suggests potential overvaluation. The absence of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

Sustained revenue growth indicates successful market expansion and product adoption, enhancing long-term business prospects.

Cash Flow Management

Strong cash flow management ensures liquidity and operational flexibility, supporting future investments and stability.

Profitability

Improved profitability margins indicate effective cost management and pricing strategies, contributing to long-term financial health.

Negative Factors

High Growth Risks

Rapid growth can strain resources and lead to operational challenges, potentially impacting long-term sustainability if not managed well.

Historical Leverage

Past leverage levels could pose risks if growth slows, as debt obligations may limit financial flexibility and increase vulnerability.

Valuation Concerns

Perceived overvaluation may lead to investor caution, affecting stock performance and capital raising ability if market conditions change.

Exosens Business Overview & Revenue Model

Company Description

Exosens engages in the development, manufacture, and sale of electro-optical technologies in the fields of amplification, and detection and imaging in France, rest of Europe, North America, Asia, Oceania, Africa, and internationally. It offers image intensifier tubes; ultra violet, short and long wave infrared, visible - near infrared, and mid wave infrared cameras, as well as enhanced vision equipment; ion and electron, scintillation, and single photon detection products; x-ray components, neutronic imaging products, and image intensifiers for scientific applications; and gamma and neutron detectors, and mineral insulated extensions. The company also provides power tubes and microwave devices; and methane airborne detection solutions. It operates under the Photonis, Xenics, Telops, and El-Mul brand names. The company serves defense and surveillance, industrial research and control, life science and environment, and nuclear markets. The company was founded in 1937 and is based in Mérignac, France. Exosens operates as a subsidiary of HLD Europe S.C.A.

How the Company Makes Money

Exosens generates revenue through multiple channels, including direct sales of its consumer electronics and smart devices, subscription services for health monitoring and data analytics, and partnerships with healthcare providers and technology firms. Key revenue streams include the sale of wearable technology that tracks health metrics, licensing fees from proprietary technology used in third-party products, and recurring revenue from subscriptions to software platforms that analyze user data for health and wellness insights. Additionally, collaborations with industry partners in the healthcare sector bolster its earnings by expanding market reach and integrating Exosens products into broader health management solutions.

Exosens Financial Statement Overview

Summary

Exosens has shown remarkable improvement across its financial statements, with strong revenue and profitability growth, a solid balance sheet with significantly reduced debt, and excellent cash flow generation. The company is on a solid trajectory, but attention should be paid to managing potential risks associated with high growth rates and historical leverage.

Income Statement

Exosens demonstrated strong revenue growth with a 23.58% increase in 2024 over 2023. The company's gross profit margin improved to 57.23%, indicating efficient production and sales strategies. Net profit margin has also increased to 7.79%, reflecting enhanced profitability. The EBIT and EBITDA margins are robust at 19.51% and 29.23% respectively, highlighting effective operational management.

Balance Sheet

Exosens has significantly improved its financial position, reducing total debt drastically and increasing stockholders' equity, resulting in a healthier debt-to-equity ratio of 0.03. The equity ratio of 50.50% suggests a strong asset base relative to liabilities, although the high growth and leverage in previous years indicate potential risks.

Cash Flow

The company shows impressive cash flow management with a substantial increase in free cash flow and operating cash flow. The operating cash flow to net income ratio is strong at 3.13, indicating good cash generation relative to net earnings. The free cash flow to net income ratio is excellent, showcasing the company's ability to generate cash from its operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	394.10M	318.80M	200.75M	166.17M	149.86M
Gross Profit	225.60M	176.81M	113.95M	100.03M	91.83M
EBITDA	115.20M	83.91M	51.25M	-101.18M	36.51M
Net Income	30.70M	17.14M	11.21M	-148.97M	-15.83M
Balance Sheet
Total Assets	817.00M	656.41M	529.25M	460.52M	598.10M
Cash, Cash Equivalents and Short-Term Investments	150.20M	44.82M	29.00M	18.34M	31.74M
Total Debt	10.90M	311.77M	248.97M	208.11M	442.56M
Total Liabilities	404.40M	452.35M	346.20M	288.41M	501.00M
Stockholders Equity	412.60M	204.06M	183.05M	172.11M	97.10M
Cash Flow
Free Cash Flow	96.20M	19.53M	25.69M	23.07M	30.35M
Operating Cash Flow	96.20M	50.46M	47.48M	42.66M	44.12M
Investing Cash Flow	-72.70M	-99.64M	-55.48M	-21.26M	-13.77M
Financing Cash Flow	76.30M	35.49M	20.26M	-36.83M	-5.01M

Exosens Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EXENS, the sentiment is Positive. The current price of 43.65 is above the 20-day moving average (MA) of 40.34, above the 50-day MA of 40.20, and above the 200-day MA of 33.32, indicating a bullish trend. The MACD of 1.02 indicates Negative momentum. The RSI at 60.24 is Neutral, neither overbought nor oversold. The STOCH value of 67.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:EXENS.

Exosens Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXENS	70 Outperform	€2.22B	39.17		0.23%	22.05%	2658.04%
ALICA	64 Neutral	54.67M	14.93	12.00%	1.92%	1.20%	-16.85%
LACR	54 Neutral	34.65M	-1.03	-24.77%	9.46%	-16.51%	-890.86%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%